![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Lilly Announces $8 Billion Acquisition of Loxo Oncology
Lilly Announces $8 Billion Acquisition of Loxo Oncology
![Eli lilly logo](https://www.fdanews.com/ext/resources/test/Drug-Images4/Lilly_Logo.jpg?t=1616695880&width=430)
January 14, 2019
Eli Lilly announced plans to purchase drug developer Loxo Oncology for $8 billion in cash.
Lilly noted that Loxo could launch a drug in 2020 targeting an abnormality occurring in several tumor types relating to thyroid and lung cancers.
Projected to close by the end of the first quarter of 2019, the deal comes shortly after Bristol-Myers Squibb announced its acquisition of Celgene, also an oncology drug producer.
Upcoming Events
-
21Oct